Latest news


PCI Biotech to present at SACHS Associates 14th Annual Biotech in Europe Forum

Posted on Sep 30, 2014

Lysaker, September 30, 2014 – PCI Biotech will be presenting at SACHS Associates 14th Annual Biotech in Europe Forum for Global Partnering & Investment in Basel, Switzerland. About the 14th Annual Biotech in Europe Forum (September 30 – October 1, 2014): The forum is recognised as the leading international stage for those interested in investing and […]

Second quarter and first half year 2014 results

Posted on Aug 26, 2014

Lysaker, 26 August 2014 – PCI Biotech presented the company’s second quarter and first half year 2014 report 26 August 2014 at 08:00 at Felix Konferansesenter, Oslo. The presentation and Q2 and first half year 2014 report are attached below: Q2 2014 Presentation Q2 2014 Report

Successful completion of the second group in the intra-tumour light dose escalation part of the ENHANCE study

Posted on Aug 22, 2014

Lysaker, 22 August 2014 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the treatment evaluation of the second group in the intra-tumour light dose escalation part of the ENHANCE study has been completed.  ENHANCE is a phase II study of Amphinex® in combination with the cytotoxic agent bleomycin in recurrent head and […]